Gates Foun­da­tion backs a new sick­le cell CRISPR ap­proach; Sid­dhartha Mukher­jee's Vor adds a new CAR-T

CRISPR/Cas9 play­er In­tel­lia Ther­a­peu­tics has a new backer — the Bill and Melin­da Gates Foun­da­tion.

The char­i­ty is spon­sor­ing re­search for in vi­vo sick­le cell dis­ease treat­ments us­ing their gene-edit­ing tech­nol­o­gy. Fi­nan­cial terms for the grant were not dis­closed, but the funds will be used to ad­vance In­tel­lia’s pre­clin­i­cal pro­grams for edit­ing hematopoi­et­ic stem cells us­ing the com­pa­ny’s pro­pri­etary non-vi­ral de­liv­ery sys­tems.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER